Avalo Therapeutics, Inc.
AVTXDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
FP01
Chronic Refractory Cough
AVTX-002
Non-Eosinophilic Asthma
CERC-301
Major Depressive Disorder
AVTX-009 Regimen 1
Hidradenitis Suppurativa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FP01 | Phase 2 | Chronic Refractory Cough | - | - |
AVTX-002 | Phase 2 | Non-Eosinophilic Asthma | - | - |
CERC-301 | Phase 2 | Major Depressive Disorder | - | - |
AVTX-009 Regimen 1 | Phase 2 | Hidradenitis Suppurativa | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Avalo Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Avalo Therapeutics, Inc.'s (AVTX) pipeline across Phase 2. Its lead program is FP01 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Avalo Therapeutics, Inc.'s next FDA catalyst?→
Avalo Therapeutics, Inc.'s (AVTX) next tracked catalyst is a Earnings expected November 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AVTX biotech catalysts?→
Add AVTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Avalo Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.